|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2010-8-2
|
|
pubmed:abstractText |
Long-term oral corticosteroid (OCS) therapy is associated with significant burden on patients and healthcare resources; treatments that may help reduce their use are important to improve asthma management.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1532-3064
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
104
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1381-5
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20599369-Adrenal Cortex Hormones,
pubmed-meshheading:20599369-Anti-Asthmatic Agents,
pubmed-meshheading:20599369-Antibodies, Anti-Idiotypic,
pubmed-meshheading:20599369-Antibodies, Monoclonal,
pubmed-meshheading:20599369-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:20599369-Asthma,
pubmed-meshheading:20599369-Databases, Factual,
pubmed-meshheading:20599369-Female,
pubmed-meshheading:20599369-France,
pubmed-meshheading:20599369-Germany,
pubmed-meshheading:20599369-Hospitalization,
pubmed-meshheading:20599369-Humans,
pubmed-meshheading:20599369-Male,
pubmed-meshheading:20599369-Middle Aged,
pubmed-meshheading:20599369-Respiratory Hypersensitivity
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data.
|
|
pubmed:affiliation |
Département de Pharmacologie, CHU Pellegrin-Carreire, de Bordeaux - Université Victor Segalen, Bordeaux, France. mathieu.molimard@pharmaco.u-bordeaux2.fr
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
